The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

"Very lame and imperfect theories are sufficient to suggest useful experiments which serve to correct those theories and give birth to others more perfect. These, then occasion farther experiments ...

A NEW study reveals that inhibitors of cyclooxygenase 1 (COX-1), including the common drug aspirin, could enhance immune responses to cancer metastasis, offering hope for preventing recurrence in ...

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

THURSDAY, April 17, 2025 (HealthDay News) — Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for ...

This study sought to determine whether the SOCS3/JAK/STAT3 signaling pathway, which controls macrophage polarization, contributes to the cardiotoxicity caused by PD-1/PD-L1 inhibitors. The PD-1/PD-L1 ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them ...

Novel potent and selective platelet inhibitors exhibit high antithrombotic efficiencies but their clinical efficacy in preventing major adverse cardiovascular events remains to be established.

REC-3565 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor designed using Recursion’s AI-driven multi-parameter optimization approach. MALT1, a key ...